Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMDC versus placebo for female stress urinary incontinence
NL-OMON39970Phase 3Withdrawn
- Sponsor
- William Cook Europe
- Start
- Apr 2013
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in stress urinary incontinence (SUI) comparing AMDC injection with Placebo injection (2 arms). Primary endpoints: Effectiveness at 12 months and Safety at 12 months. Planned start Apr 2013; status: withdrawn.
02
Drugs
AMDC-USR
03
Conditions
stress urinary incontinence (SUI)
Beyond the preview
Go deeper on NL-OMON39970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39970.